Harmony's WAKIX grows 12% to $268.9M, but royalties and milestones squeeze profit

The quarter in numbers

Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026, up 12% from $239.5 million a year earlier. The company said it remains on track for full-year WAKIX net revenue of $1.0 billion to $1.04 billion, a range it reiterated rather than changed.

Profit moved the other way. Net income was $48.2 million, or $0.81 per diluted share, against $50.9 million, or $0.87, in the third quarter of 2025. The company attributed the decline primarily to higher milestone charges and new MSN royalty charges. Revenue grew while earnings fell, so the quarter was about how costs scaled with the franchise as much as demand.

Demand: patient adds carry the story

Harmony credited demand rather than pricing, though the release gives no price or volume split. The estimated average number of patients grew by 400 to 9,350 in the quarter, and the company said five of the last six quarters have delivered more than 400 patient additions.

The company said the expanded field sales, remote sales, field reimbursement and patient outreach teams were all hired, trained and fully deployed in Q2. It also pointed to headroom: roughly 170,000 people in the U.S. live with narcolepsy, fewer than 50% are diagnosed, and brand penetration is about 20%. The release cites about 80,000 diagnosed patients and says WAKIX has coverage for more than 80% of covered lives.

Costs and margins: royalties bite

Cost of product sold rose 35% to $80.7 million, or 30% of WAKIX net revenue, from $59.7 million, or 25%, a year earlier. The company said the higher ratio was primarily driven by new royalties under the Novitium license agreement. That is a structural change in cost of goods, not a one-quarter effect.

Total operating expenses rose 17% to $134.0 million. R&D was $71.7 million, up 30% from $55.0 million, primarily driven by a $25.0 million charge for a milestone achieved under the MSN license agreement. The release says this was partially offset by a $15.0 million ZYN002 clinical milestone charge in the prior-year period. Sales and marketing rose 18% to $34.7 million on field-team expansion. G&A fell 7% to $27.7 million, which the company linked to lower stock-based compensation.

Cash, cash equivalents and investments reached $1,051.6 million at September 30, 2026, from $882.5 million at December 31, 2025, even as milestone payments continue. The company lists R&D investment, especially BP-205, success-based milestones and business development as capital allocation priorities.

Pipeline and regulatory catalysts

The lead pipeline item is BP-205, an orexin-2 receptor agonist discovered by Teijin Pharma and developed in partnership with Bioprojet. Preliminary data from a 14-day multiple-ascending dose study in 94 healthy volunteers, at 0.1, 0.6, 1 and 3 mg once daily, showed mean T(max) of about 60 minutes and an effective half-life of about 29 hours. Headache was the most common adverse event, in about 25% of participants. On-target insomnia was below 20% at all doses, and urinary frequency and urgency were below 20% at 1 mg and 3 mg only. The company reported no liver or visual adverse events, no serious or severe adverse events, and no clinically significant cardiovascular events or EKG abnormalities. Phase 1b data in sleep-deprived healthy volunteers are expected in Q1 2027, with Phase 2 studies in multiple CNS indications by mid-2027.

Closer to market, the pitolisant GR NDA carries a PDUFA date of April 1, 2027, with launch targeted for 1H 2027. The company said GR allows treatment initiation at a therapeutic dose without titration. Pitolisant HD has Phase 3 trials in narcolepsy and idiopathic hypersomnia with topline data in 2027 and a targeted 2028 PDUFA date. The TEMPO Phase 3 trial in Prader-Willi syndrome and the two EPX-100 Phase 3 trials in rare epilepsies are all guided to mid-2027 topline data and 2028 PDUFA dates. Updated 18-month ARGUS open-label extension data are due at AES in December 2026.

Exclusivity and the legal calendar

Harmony said its multi-layered IP strategy, together with settlements with 6 of the 7 ANDA filers, supports confidence in WAKIX exclusivity to March 2030, inclusive of six months of pediatric exclusivity. The company said completing TEMPO fulfils the last agreed FDA requirement for that extension.

The near-term dates matter most. Closing arguments in the AET ANDA bench trial, covering the polymorph and method-of-use patents ('197 and '947), were held October 22, 2026, with a ruling expected around the 30-month stay expiry in February 2027. In the separate amorphous-form ('920) case against AET Pharma US and Sandoz, a preliminary injunction hearing is set for January 26, 2027, with a decision expected by February 14, 2027. The '920 trial itself is expected sometime in 2029.

What to watch next

Leadership changes on January 1, 2027, when COO Peter Anastasiou succeeds retiring CEO Jeffrey Dayno, MD. The company said the transition does not change strategic priorities or milestone timing. Business development is also in focus: Harmony says it is seeking assets that add revenue in 2028 to 2032 and innovative long-term pipeline assets, in sleep, epilepsy, rare CNS and broader CNS indications.

The release gives no nine-month revenue figure, so the Q4 contribution needed to land inside the guided range cannot be derived from it.